title: [Biologic therapies in the systemic vasculitides].
abstract: Several biological therapies have been evaluated in systemic vasculitis. Anti TNF-α agents may have a role in the treatment of Takayasu's arteritis and probably in giant cell arteritis. In Kawasaki's disease, infliximab is an option in subjects with intravenous immunoglobulin-resistant disease. Anti TNF-α cannot be recommended to treat ANCA-associated vasculitis. Anti-T lymphocyte globulin and alemtuzumab could have a role in the treatment of ANCA associated vasculitis, although current information about these two biological treatments comes from conventional resistant treatment cases, so the high incidence of complications and relapses observed with these treatment may be intrinsic to the severity of the disease and not related to the biological agents.
authors.affiliation: Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Facultad de Medicina de Universidad Nacional Autónoma de México, México DF, México.
authors.forename: Mariano Arturo
authors.initials: MA
authors.lastname: Díaz-Orta
authors.forename: Jorge
authors.initials: J
authors.lastname: Rojas-Serrano
mesh_terms: D000074323:Alemtuzumab; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001691:Biological Therapy; D000068800:Etanercept; D013700:Giant Cell Arteritis / Q000188:drug therapy; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D016898:Interferon-alpha / Q000627:therapeutic use; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000037:antagonists & inhibitors; D056647:Systemic Vasculitis / Q000188:drug therapy*; D013601:T-Lymphocytes; D013625:Takayasu Arteritis / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D016898:Interferon-alpha; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha; D000074323:Alemtuzumab; D000069285:Infliximab; D000068800:Etanercept